JUNIUS DANIEL M 4

What Happened

• Daniel M. Junius, a director of IDEXX Laboratories (IDXX), received two equity awards on 2026-05-12: 525 option awards (derivative) and 234 restricted stock units (RSUs). The filing reports $0.00 per share (grant value listed as $0 in the Form 4); these are grants/awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-05-12; Form 4 filed 2026-05-14 (filed two days after the transaction).
• Award details: 525 option awards (derivative) and 234 RSUs, both reported as acquired at $0.00.
• Vesting: Both awards vest in one installment on the one-year anniversary of the grant or on the date of the 2027 annual meeting of shareholders, whichever is earlier (see footnotes F1 and F2).
• Shares owned after transaction: Not disclosed in the provided filing.
• Transaction code: A = Award/Grant. No indication of a 10b5-1 plan, tax withholding sale, or late filing in the submitted information.

Context

• RSUs are contingent rights to receive shares when they vest; options are derivative rights to purchase shares (exercise required to convert to owned shares). These are typical forms of director compensation and do not represent an open-market buy or sell. No sale occurred, so this is a compensation grant rather than a trading signal.